- Home
- PNW vs BMRN Comparison
PNW vs BMRN Comparison
Compare PNW & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNW | BMRN |
|---|---|---|
| Founded | 1985 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 10.0B |
| IPO Year | 1994 | 1999 |
Fundamental Metrics
Financial Performance| Metric | PNW | BMRN |
|---|---|---|
| Price | $102.91 | $58.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 17 |
| Target Price | ★ $97.25 | $87.24 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.05 | 1.80 |
| Revenue | ★ $5,339,939,000.00 | $1,313,646,000.00 |
| Revenue This Year | $5.23 | $13.34 |
| Revenue Next Year | $7.03 | $11.42 |
| P/E Ratio | ★ $20.11 | $32.80 |
| Revenue Growth | 4.20 | ★ 17.62 |
| 52 Week Low | $85.32 | $50.76 |
| 52 Week High | $103.21 | $73.18 |
Technical Indicators
Market Signals| Indicator | PNW | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 42.57 |
| Support Level | $86.96 | $56.08 |
| Resistance Level | $103.21 | $60.52 |
| Average True Range (ATR) | 1.89 | 2.25 |
| MACD | -0.17 | -0.41 |
| Stochastic Oscillator | 87.79 | 1.80 |
Price Performance
Historical ComparisonAbout PNW Pinnacle West Capital Corporation
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.